Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorMemorial Sloan Kettering Cancer Center
About this trial
The main purpose of this study is to see if IgPro20 can prevent infection in people with multiple myeloma (MM) who have hypogammaglobulinemia from receiving bispecific monoclonal antibodies (BsAbs).
Eligibility criteria
Qualifiers
Diagnosis of RRMM receiving a commercially available bispecific antibody
Received at least 1 but no more than 4 cycles of BsAb
Males or females greater than or equal to 18 years old at the time of consent
ECOG ≤ 3
Disqualifiers
HSCT within 3 months before enrollment
Planned CAR-T therapy in the next 6 months
>1 major (deep-seated) infection within the preceding 3 months
HIV infection, Active HCV, or Active HBV infection
Trial design
Treatments tested in this trial
- IgPro20
Treatment groups
100 Participants
are divided into 2 treatment groupsLocations
8Memorial Sloan Kettering Basking Ridge (All Protocol Activities)10065, Basking RidgeNew Jersey, United States
Memorial Sloan Kettering Monmouth (All Protocol Activities)07748, MiddletownNew Jersey, United States
Memorial Sloan Kettering Bergen (All Protocol Activities)07645, MontvaleNew Jersey, United States
Memorial Sloan Kettering Suffolk-Commack (All Protocol Activity)11725, CommackNew York, United States
Sponsors and collaborators
Memorial Sloan Kettering Cancer Center
Lead sponsor
Source ClinicalTrials.gov